FLKS Description — Salarius Pharmaceuticals Inc
Flex Pharma is a biotechnology company that is developing treatments for muscle cramps, spasms and spasticity associated with severe neurological conditions and exercise-associated muscle cramps. Co.'s primary drug product candidate, FLX-787, is in exploratory Phase 2 clinical trials in Australia in patients with multiple sclerosis and in two Phase 2 clinical trials in the U.S. One Phase 2 clinical trial is in patients with motor neuron disease, who suffer from muscle cramps. The other Phase 2 clinical trialis in patients with Charcot-Marie-Tooth disease, who suffer from muscle cramps. Co. also has a consumer product, HOTSHOT®, to prevent and treat exercise-associated muscle cramps.
|
Free FLKS Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts Forecast: FLKS Price Target Based on data provided by Zacks Investment Research via Quandl.com |
|